HER2 antibody composition

A kind of composition, antibody technology, applied in the composition field of amino acid sequence variant

Active Publication Date: 2007-08-22
F HOFFMANN LA ROCHE & CO AG
View PDF126 Cites 32 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Although EGF and TGFα do not bind HER2, EGF stimulates EGFR and HER2 to form a heterodimer, which activates EGFR and leads to transphosphorylation of HER2 in the heterodimer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HER2 antibody composition
  • HER2 antibody composition
  • HER2 antibody composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0296] Identification of the composition of PERTUZUMAB

[0297] Pertuzumab is a recombinant humanized monoclonal antibody produced on the basis of human IgG1() framework. It contains two heavy chains (448 residues) and two light chains (214 residues). The two heavy chains are linked by two interchain disulfide bonds, and each light chain is attached to the heavy chain by one interchain disulfide bond. There is an N-linked glycosylation site at Asn-299 of both heavy chains in the Fc region of Pertuzumab. Pertuzumab with HERCEPTIN  (Trastuzumab) differ in the epitope-binding regions of the light chain (12 amino acid difference) and heavy chain (30 amino acid difference). Because of these differences, Pertuzumab binds to a completely different epitope on the HER2 receptor. Binding of Pertuzumab to the HER2 receptor on human epithelial cells prevents it from forming complexes with other members of the HER receptor family (Agus et al., Cancer Cell 2:127-137 (2002)). By blocki...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.

Description

field of invention [0001] The present invention contemplates compositions comprising primary species HER2 antibodies that bind HER2 domain II and amino acid sequence variants thereof comprising amino-terminal leader extensions. The invention also relates to pharmaceutical formulations comprising said composition and to the therapeutic use of said composition. Background of the invention [0002] HER2 antibody [0003] The HER family of receptor tyrosine kinases are important mediators of cell growth, differentiation and survival. This receptor family includes four distinct members: epidermal growth factor receptor (EGFR, ErbB1 or HER1), HER2 (ErbB2 or p185 neu ), HER3 (ErbB3) and HER4 (ErbB4 or tyro2). [0004] EGFR, encoded by the erbB1 gene, has been recognized as the cause of human malignancies. In particular, increased expression of EGFR has been observed in breast, bladder, lung, head, neck, and gastric cancers, as well as glioblastoma. Elevated expression of the E...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/32
CPCC07K2317/24C07K16/32C07K2316/96A61K2039/505A61K39/395C07K2317/73A61P15/00A61P31/00A61P35/00A61P35/04A61P43/00A61K39/39558
Inventor 高涌祥马丁·范德莱安
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap